Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study.
Brooke E Wilson, Susannah Jacob, Mei Ling Yap...
https://pubmed.ncbi.nlm.nih.gov/31078462/Actively Recruiting
Led by Sun Yat-sen University · Updated on 2026-10-14
3000
Participants Needed
1
Research Sites
43 weeks
Total Duration
Researchers are studying HR20013, a newly approved medicine in China, to prevent nausea and vomiting caused by cancer treatment. This real-world, observational study involves about 3,000 patients with cancer receiving HR20013 as part of their routine care at over 30 hospitals. The study includes a subgroup of 100 patients with mild to moderate liver impairment to better understand the medicines use in different patient groups. Participants receive HR20013 through an intravenous infusion before their anticancer therapy. The study observes patients receiving either HR20013 alone or in combination with other treatments, following usual clinical care without additional study-mandated interventions. Two groups are included patients with mild to moderate liver impairment and those without liver impairment. Both groups are monitored to evaluate how well HR20013 prevents nausea and vomiting during acute, delayed, and overall phases after chemotherapy. Throughout the study, patients report episodes of nausea and vomiting using standard criteria, and researchers assess adverse drug reactions. Quality of life is measured using a specific questionnaire related to emesis. Data collection follows routine clinical visits and practices, tracking safety and effectiveness over each treatment cycle lasting 21 days, continuing for up to 30 days after the last HR20013 dose. The study aims to guide better clinical use of HR20013 for preventing chemotherapy-induced nausea and vomiting.
CONDITIONS
HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study
L
Li Zhang, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-sen University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Each treatment cycle lasts 21 days; monitoring continues up to 30 days after the last dose
Participants receive HR20013 infusion as part of routine cancer care before chemotherapy. Researchers observe and collect data on nausea, vomiting, and side effects during and after treatment cycles.
Visits follow routine clinical practice
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Brooke E Wilson, Susannah Jacob, Mei Ling Yap...
https://pubmed.ncbi.nlm.nih.gov/31078462/Huaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang...
https://pubmed.ncbi.nlm.nih.gov/39621965/Sun Yat-sen University
Lead Sponsor